Patents Assigned to Sun Pharmaceutical Industries Limited
-
Patent number: 11951153Abstract: Provided herein are formulations for topical ophthalmic formulations containing 0.087-0.093 wt % of cyclosporine, and methods of making and using such formulations. In some aspects and embodiments the formulations may include a polyoxyl lipid or fatty acid, and/or a polyalkoxylated alcohol and may include nanomicelles. Also included herein are methods of treating or preventing diseases or conditions, such as ocular diseases or conditions.Type: GrantFiled: September 26, 2022Date of Patent: April 9, 2024Assignee: SUN PHARMACEUTICAL INDUSTRIES LIMITEDInventors: Sidney L. Weiss, Ashim K. Mitra, Eugene J. McNally
-
Publication number: 20240050446Abstract: The present invention relates to a method of treating blepharitis comprising administering to the affected eye of a subject an effective amount of an active ingredient in an ophthalmically acceptable vehicle for a sufficient period of time to treat blepharitis. The active ingredient comprises a glucocorticoid in an ophthalmically acceptable vehicle, such as DuraSite® 2. Additionally, the present invention discloses a kit that includes: (a) a composition comprising about 0.1% by weight dexamethasone in an ophthalmically acceptable vehicle and, optionally, (b) instructions for using the composition for the treatment of blepharitis.Type: ApplicationFiled: February 24, 2022Publication date: February 15, 2024Applicant: SUN PHARMACEUTICAL INDUSTRIES LIMITEDInventor: Lyle BOWMAN
-
Patent number: 11873328Abstract: The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.Type: GrantFiled: August 1, 2022Date of Patent: January 16, 2024Assignee: SUN PHARMACEUTICAL INDUSTRIES LIMITEDInventors: Rajamannar Thennati, Nishith Chaturvedi, Vinod Sampatrao Burade, Pradeep Dinesh Shahi, Muthukumaran Natarajan, Ravishankara Madavati Nagaraja, Rishit Mansukhlal Zalawadia, Vipulkumar Shankarbhai Patel, Kunal Pandya, Brijeshkumar Patel, Dhiren Rameshchandra Joshi, Krunal Harishbhai Soni, Abhishek Tiwari
-
Patent number: 11865089Abstract: The present invention provides a ready to use stable aqueous dosage form of norepinephrine comprising an aqueous solution of norepinephrine or its pharmaceutically acceptable salt, one or more sulfite antioxidants and an ion chelator. The present invention also provides an infusion container filled with an aqueous solution of norepinephrine or its pharmaceutically acceptable salt, wherein the said solution is stable for a prolonged period of time and can be terminally sterilized by autoclaving.Type: GrantFiled: October 18, 2021Date of Patent: January 9, 2024Assignee: SUN PHARMACEUTICAL INDUSTRIES LIMITEDInventors: Samarth Kumar, Maheshkumar Parasmal Soni, Praveen Kumar Srivastava, Prashant Kane, Subhas Balaram Bhowmick
-
Patent number: 11866477Abstract: The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.Type: GrantFiled: August 12, 2022Date of Patent: January 9, 2024Assignee: SUN PHARMACEUTICAL INDUSTRIES LIMITEDInventors: Rajamannar Thennati, Nishith Chaturvedi, Vinod Sampatrao Burade, Pradeep Dinesh Shahi, Muthukumaran Natarajan, Ravishankara Madavati Nagaraja, Rishit Mansukhlal Zalawadia, Vipulkumar Shankarbhai Patel, Kunal Pandya, Brijeshkumar Patel, Dhiren Rameshchandra Joshi, Krunal Harishbhai Soni, Abhishek Tiwari
-
Publication number: 20230338366Abstract: A parenteral unit dosage form comprising an aqueous solution of dihydroergotamine or pharmaceutically acceptable salt thereof as a sole active ingredient, one or more pH adjusting agents, and optionally one or more co-solvents, wherein the pH of the aqueous solution is such that it contains substantially lower amount of impurity of Formula I and impurity of Formula II as compared to aqueous solution having a pH of 4.0 or less, when the parenteral unit dosage form is stored at 25° C. and 60% relative humidity for at least three months.Type: ApplicationFiled: April 24, 2023Publication date: October 26, 2023Applicant: SUN PHARMACEUTICAL INDUSTRIES LIMITEDInventors: Alpesh GOYANI, Deepak SINGODIA, Bhaskar PALLERLA, Sudeep Kumar AGRAWAL, Subhas Balaram BHOWMICK, Rajamannar THENNATI
-
Patent number: 11793719Abstract: The present invention relates to a method for enabling hospitals or clinics to administer a dose of a drug to patients in need thereof while avoiding steps of manipulation, dilution, reconstitution, dispensing, sterilization, transfer, handling or compounding before intravenous administration. The present invention further relates to a perfusion system comprising different sets of perfusion containers, each container comprising a ready-to-infuse, stable, sterile, aqueous perfusion solution of a drug, wherein the set of perfusion containers alone or in combination provides for direct intravenous administration of a desired dose of the drug to a patient in need thereof, such that the delivered dose is equal to or within ±5% of the calculated dose.Type: GrantFiled: September 20, 2022Date of Patent: October 24, 2023Assignee: SUN PHARMACEUTICAL INDUSTRIES LIMITEDInventors: Samarth Kumar, Prashant Kane, Subhas Balaram Bhowmick, Kirti Ganorkar, Nishit Patel, Ashish Anilrao Dubewar, Umeshkumar Mukeshbhai Patel
-
Publication number: 20230303678Abstract: The disclosure relates to an anti-IL-23p19 antibody hum13B8-b or antigen binding fragment thereof and its use in the treatment of plaque psoriasis of the scalp.Type: ApplicationFiled: January 24, 2023Publication date: September 28, 2023Applicant: SUN PHARMACEUTICAL INDUSTRIES LIMITEDInventors: Judilyn FUENTES-DUCULAN, Tushar NISHANDAR, Rocco BALLERINI, Kristine NOGRALES, Siu-Long YAO
-
Publication number: 20230285301Abstract: The present invention discloses an extended release multi-particulate sprinkle composition comprising a plurality of discrete units, each discrete unit comprising quetiapine or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients.Type: ApplicationFiled: May 15, 2023Publication date: September 14, 2023Applicant: Sun Pharmaceutical Industries LimitedInventors: Amit KUMAR, Ravindra AGARWAL, Pulak Kumar METIA, Kalaiselvan RAMARAJU, Sumit MADAN, Romi Barat SINGH
-
Publication number: 20230248724Abstract: A method is provided for the acute treatment of migraine headaches with or without aura by injecting dihydroergotamine mesylate into a subject. The method includes storing the dihydroergotamine mesylate in an autoinjector at room temperature in a foil pouch. The method further includes removing the autoinjector from the pouch; removing a cap of the autoinjector; pushing the autoinjector down against an injection site of the subject to depress a safety guard; pressing and releasing an activation button on the autoinjector to start injection; and holding the autoinjector against the injection site for at least 10 seconds irrespective of whether a click is generated. The method further includes confirming that the injection is complete by viewing a change of color in a viewing window of the autoinjector, and lifting the autoinjector up away from the injection site and allowing the guard to drop down and lock over a needle.Type: ApplicationFiled: January 13, 2022Publication date: August 10, 2023Applicant: SUN PHARMACEUTICAL INDUSTRIES LIMITEDInventors: Satyashodhan Babasaheb PATIL, Sudeep Kumar AGRAWAL, Subhas Balaram BHOWMICK, Prashant KANE
-
Patent number: 11690805Abstract: The present invention discloses an extended release multi-particulate sprinkle composition comprising a plurality of discrete units, each discrete unit comprising quetiapine or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients.Type: GrantFiled: December 14, 2021Date of Patent: July 4, 2023Assignee: Sun Pharmaceutical Industries LimitedInventors: Amit Kumar, Ravindra Agarwal, Pulak Kumar Metia, Kalaiselvan Ramaraju, Sumit Madan, Romi Barat Singh
-
Publication number: 20230117549Abstract: A method of providing and/or injecting octreotide acetate to a subject in need thereof includes storing the octreotide acetate in a cartridge of a multi-use multi-dose injector provided with a variable dose setter and actuator. The injector includes a needle configured for subcutaneous administration of the octreotide acetate, the octreotide acetate having a concentration of 2,500 ?g/mL. The method further includes permitting setting of a dose of the octreotide acetate by rotation of the variable dose setter. The injector is configured to provide at least one audible feedback during the rotation. The method further includes operating the actuator to deliver the octreotide acetate from the cartridge through the needle to treat the subject. The injector is provided with multiple surface portions.Type: ApplicationFiled: December 20, 2022Publication date: April 20, 2023Applicant: SUN PHARMACEUTICAL INDUSTRIES LIMITEDInventors: Satyashodhan Babasaheb PATIL, Sudeep Kumar AGRAWAL, Subhas Balaram BHOWMICK, Prashant KANE
-
Patent number: 11534553Abstract: A method of providing and/or injecting octreotide acetate to a subject in need thereof includes storing the octreotide acetate in a cartridge of a multi-use multi-dose injector provided with a variable dose setter and actuator. The injector includes a needle configured for subcutaneous administration of the octreotide acetate, the octreotide acetate having a concentration of 2,500 ?g/mL. The method further includes providing, on the injector, a plurality of indicia only at prescribed doses of 50 ?g, 100 ?g, 150 ?g and 200 ?g settable via the dose setter without indicia between said prescribed doses; and permitting setting of a dose of the octreotide acetate by rotation of the variable dose setter, wherein the injector is configured to provide at least one audible feedback during the rotation.Type: GrantFiled: December 29, 2021Date of Patent: December 27, 2022Assignee: SUN PHARMACEUTICAL INDUSTRIES LIMITEDInventors: Satyashodhan Babasaheb Patil, Sudeep Kumar Agrawal, Subhas Balaram Bhowmick, Prashant Kane
-
Patent number: 11523996Abstract: The present invention relates to extended release liquid compositions of metformin. The extended release liquid compositions are in the form of suspensions or reconstituted powder for suspensions. Said extended release liquid compositions comprise cores of metformin coated with a release-controlling agent, wherein the coated cores are dispersed in a suspension base. Said extended release liquid compositions provide the desired uniform extended release profile throughout the shelf-life of the composition. Furthermore, said extended release liquid compositions are bioequivalent to a reference composition. It also relates to processes for the preparation of said extended release liquid compositions.Type: GrantFiled: November 1, 2017Date of Patent: December 13, 2022Assignee: SUN PHARMACEUTICAL INDUSTRIES LIMITEDInventors: Romi Barat Singh, Ashish Kumar, Rajesh Srikrishan Shear, Satish Kumar Jain, Paras P. Jain
-
Patent number: 11510878Abstract: The present invention relates to an extended release multiparticulate composition comprising a plurality of discrete units, each discrete unit comprising ranolazine or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipients. The said multiparticulate composition is sprinkled onto soft foods or liquids for oral administration. Further, the multiparticulate composition is bioequivalent to the marketed extended release tablet. It further relates to a process of preparation of said multiparticulate composition and method of treatment of patients suffering from angina by administering said composition.Type: GrantFiled: December 21, 2020Date of Patent: November 29, 2022Assignee: Sun Pharmaceutical Industries LimitedInventors: Harinder Singh, Shavej Ahmad, Romi B. Singh
-
Patent number: 11504345Abstract: The present invention relates to extended release liquid compositions of metformin. The extended release liquid compositions are in the form of suspensions or reconstituted powder for suspensions. Said extended release liquid compositions comprise cores of metformin coated with a release-controlling agent, wherein the coated cores are dispersed in a suspension base. Said extended release liquid compositions provide the desired uniform extended release profile throughout the shelf-life of the composition. Furthermore, said extended release liquid compositions are bioequivalent to a reference composition. It also relates to processes for the preparation of said extended release liquid compositions.Type: GrantFiled: June 23, 2020Date of Patent: November 22, 2022Assignee: SUN PHARMACEUTICAL INDUSTRIES LIMITEDInventors: Romi Barat Singh, Ashish Kumar, Rajesh Srikrishan Shear, Satish Kumar Jain, Paras P. Jain
-
Patent number: 11485766Abstract: The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.Type: GrantFiled: December 28, 2020Date of Patent: November 1, 2022Assignee: SUN PHARMACEUTICAL INDUSTRIES LIMITEDInventors: Rajamannar Thennati, Nishith Chaturvedi, Vinod Sampatrao Burade, Pradeep Dinesh Shahi, Muthukumaran Natarajan, Ravishankara Madavati Nagaraja, Rishit Mansukhlal Zalawadia, Vipulkumar Shankarbhai Patel, Kunal Pandya, Brijeshkumar Patel, Dhiren Rameshchandra Joshi, Krunal Harishbhai Soni, Abhishek Tiwari
-
Patent number: 11447535Abstract: The present disclosure pertains to novel Glucagon like Peptide-1 (GLP-1) (7-37) analogs having an amino acid sequence with Leu or Ile at the C-terminal. The new analogs are potent GLP-1 agonists with reduced adverse effect and improved duration of action. The present disclosure further relates to acylated derivatives of the new analogs which have further improved potency and duration of action and are suitable for oral administration. The analogs of present disclosure may be useful in treatment of diabetes and obesity.Type: GrantFiled: April 5, 2019Date of Patent: September 20, 2022Assignee: Sun Pharmaceutical Industries LimitedInventors: Rajamannar Thennati, Nishith Chaturvedi, Vinod Sampatrao Burade, Pradeep Dinesh Shahi, Muthukumaran Natarajan, Ravishankara Madavati Nagaraja, Rishit Mansukhlal Zalawadia, Vipulkumar Shankarbhai Patel, Kunal Pandya, Brijeshkumar Patel, Dhiren Rameshchandra Joshi, Krunal Harishbhai Soni, Abhishek Tiwari
-
Publication number: 20220226308Abstract: A parenteral unit dosage form comprising an aqueous solution of dihydroergotamine or pharmaceutically acceptable salt thereof as a sole active ingredient, one or more pH adjusting agents, and optionally one or more co-solvents, wherein the pH of the aqueous solution is such that it contains substantially lower amount of impurity of Formula I and impurity of Formula II as compared to aqueous solution having a pH of 4.0 or less, when the parenteral unit dosage form is stored at 25° C. and 60% relative humidity for at least three months.Type: ApplicationFiled: April 4, 2022Publication date: July 21, 2022Applicant: SUN PHARMACEUTICAL INDUSTRIES LIMITEDInventors: Alpesh GOYANI, Deepak SINGODIA, Bhaskar PALLERLA, Sudeep Kamar AGRAWAL, Subhas Balaram BHOWMICK, Rajamannar THENNATI
-
Publication number: 20220118188Abstract: A method of providing and/or injecting octreotide acetate to a subject in need thereof includes storing the octreotide acetate in a cartridge of a multi-use multi-dose injector provided with a variable dose setter and actuator. The injector includes a needle configured for subcutaneous administration of the octreotide acetate, the octreotide acetate having a concentration of 2,500 ?g/mL. The method further includes providing, on the injector, a plurality of indicia only at prescribed doses of 50 ?g, 100 ?g, 150 ?g and 200 ?g settable via the dose setter without indicia between said prescribed doses; and permitting setting of a dose of the octreotide acetate by rotation of the variable dose setter, wherein the injector is configured to provide at least one audible feedback during the rotation.Type: ApplicationFiled: December 29, 2021Publication date: April 21, 2022Applicant: SUN PHARMACEUTICAL INDUSTRIES LIMITEDInventors: Satyashodhan Babasaheb PATIL, Sudeep Kumar AGRAWAL, Subhas Balaram BHOWMICK, Prashant KANE